ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: Monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression

Annick D. Van Den Abbeele, Constantine Gatsonis, Daniel J. De Vries, Yulia Melenevsky, Agnieszka Szot-Barnes, Jeffrey T. Yap, Andrew K. Godwin, Lori Rink, Min Huang, Meridith Blevins, Jo Rean Sicks, Burton Eisenberg, Barry A. Siegel

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Fingerprint Dive into the research topics of 'ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: Monitoring with <sup>18</sup>F-FDG PET and correlation with genotype and GLUT4 expression'. Together they form a unique fingerprint.

Medicine & Life Sciences